Trial · NCT03932682
Results by group354
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 354
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy Endpoint: First Occurrence of Reverse Transcription-polymerase Chain Reaction (RT-PCR) Confirmed Influenza, Due to Any Influenza Type A and/or B Virus Regardless of Antigenic Match | QIVc | 104 | Cases | ||
| Efficacy Endpoint: First Occurrence of Reverse Transcription-polymerase Chain Reaction (RT-PCR) Confirmed Influenza, Due to Any Influenza Type A and/or B Virus Regardless of Antigenic Match | Comparator | 173 | Cases | ||
Efficacy Endpoint: First Occurrence of Culture Confirmed Influenza, Due to Influenza Type A and/or B Virus Antigenically Matched by Ferret Antigenicity Testing to the Strains Selected for the Seasonal Influenza Vaccine | QIVc | 44 | Cases | ||
Efficacy Endpoint: First Occurrence of Culture Confirmed Influenza, Due to Influenza Type A and/or B Virus Antigenically Matched by Ferret Antigenicity Testing to the Strains Selected for the Seasonal Influenza Vaccine | Comparator | 82 | Cases | ||
| Efficacy Endpoint: First Occurrence of Culture Confirmed Influenza Caused by Influenza Virus Strains Antigenically Dissimilar to the Influenza Strains Selected for the Seasonal Influenza Vaccine | QIVc | 20 | Cases | ||
| Efficacy Endpoint: First Occurrence of Culture Confirmed Influenza Caused by Influenza Virus Strains Antigenically Dissimilar to the Influenza Strains Selected for the Seasonal Influenza Vaccine | Comparator | 43 | Cases | ||
Efficacy Endpoint: First Occurrence of Culture Confirmed Influenza Due to Any Influenza Type A and/or Type B Virus Regardless of Antigenic Match to the Influenza Strains Selected for the Seasonal Influenza Vaccine | QIVc | 61 | Cases | ||
Efficacy Endpoint: First Occurrence of Culture Confirmed Influenza Due to Any Influenza Type A and/or Type B Virus Regardless of Antigenic Match to the Influenza Strains Selected for the Seasonal Influenza Vaccine | Comparator | 121 | Cases | ||
Efficacy Endpoint: First Occurrence of RT-PCR Confirmed Moderate-to-severe Influenza Due to Any Influenza Type A and/or Type B Virus Regardless of Antigenic Match to the Influenza Strains Selected for the Seasonal Influenza Vaccine | QIVc | 0 | Cases | ||
Efficacy Endpoint: First Occurrence of RT-PCR Confirmed Moderate-to-severe Influenza Due to Any Influenza Type A and/or Type B Virus Regardless of Antigenic Match to the Influenza Strains Selected for the Seasonal Influenza Vaccine | Comparator | 9 | Cases | ||
| Immunogenicity Endpoint: Prevaccination and Postvaccination Geometric Mean Titer (GMT) (HI Assay) | QIVc (Season 1) | A/H1N1 Day 1 HI GMT | 40.06 | 95% Confidence Interval 21.41 to 74.97 | Geometric mean titer |
| Immunogenicity Endpoint: Prevaccination and Postvaccination Geometric Mean Titer (GMT) (HI Assay) | Comparator (Season 1) | A/H1N1 Day 1 HI GMT | 44.28 | 95% Confidence Interval 24.19 to 81.07 | Geometric mean titer |
| Immunogenicity Endpoint: Prevaccination and Postvaccination Geometric Mean Titer (GMT) (HI Assay) | QIVc (Season 2) | A/H1N1 Day 1 HI GMT | 22.99 | 95% Confidence Interval 9.52 to 55.49 | Geometric mean titer |
| Immunogenicity Endpoint: Prevaccination and Postvaccination Geometric Mean Titer (GMT) (HI Assay) | Comparator (Season 2) | A/H1N1 Day 1 HI GMT | 27.50 | 95% Confidence Interval 11.60 to 65.18 | Geometric mean titer |
| Immunogenicity Endpoint: Prevaccination and Postvaccination Geometric Mean Titer (GMT) (HI Assay) | QIVc (Season 3) | A/H1N1 Day 1 HI GMT | 10.15 | 95% Confidence Interval 4.45 to 23.13 | Geometric mean titer |
| Immunogenicity Endpoint: Prevaccination and Postvaccination Geometric Mean Titer (GMT) (HI Assay) | Comparator (Season 3) | A/H1N1 Day 1 HI GMT | 8.72 | 95% Confidence Interval 3.87 to 19.60 | Geometric mean titer |
| Immunogenicity Endpoint: Prevaccination and Postvaccination Geometric Mean Titer (GMT) (HI Assay) | QIVc (Season 4) | A/H1N1 Day 1 HI GMT | 57.83 | 95% Confidence Interval 34.41 to 97.19 | Geometric mean titer |
| Immunogenicity Endpoint: Prevaccination and Postvaccination Geometric Mean Titer (GMT) (HI Assay) | Comparator (Season 4) | A/H1N1 Day 1 HI GMT | 58.00 | 95% Confidence Interval 34.81 to 96.64 | Geometric mean titer |
| Immunogenicity Endpoint: Prevaccination and Postvaccination Geometric Mean Titer (GMT) (HI Assay) | QIVc (Season 5) | A/H1N1 Day 1 HI GMT | 13.60 | 95% Confidence Interval 1.97 to 93.97 | Geometric mean titer |
| Immunogenicity Endpoint: Prevaccination and Postvaccination Geometric Mean Titer (GMT) (HI Assay) | Comparator (Season 5) | A/H1N1 Day 1 HI GMT | 13.94 | 95% Confidence Interval 1.95 to 99.61 | Geometric mean titer |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03932682/results